iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
iBio, Inc. (NYSEA:IBIO) announced it will report its fiscal 2021 second quarter financial results on February 16, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. Eastern Time for discussing results and providing updates. iBio is recognized for its FastPharming® System, which combines advanced technologies for biologics manufacturing. This system aims to produce high-quality monoclonal antibodies and vaccines. For more details, visit ibioinc.com.
- Upcoming fiscal 2021 Q2 financial results may show growth potential.
- Engagement in advanced plant-based biologics manufacturing.
- None.
BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February 16, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference code: 7891625.
About iBio, Inc.
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with the Glycaneering™ Development Services for the control and tailoring of N-glycosylation. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
When will iBio report its Q2 financial results for fiscal 2021?
How can I access the iBio conference call?
What is iBio's FastPharming® System?
